Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 478

1.

Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review.

Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, Vella S, Narciso P, Corpolongo A, Andreoni M.

J Antimicrob Chemother. 2007 Oct;60(4):724-32. Epub 2007 Aug 21. Review.

PMID:
17715125
2.
3.

Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

Mocroft A, Gill MJ, Davidson W, Phillips AN.

J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):475-82.

PMID:
11035619
4.

Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.

Kuyper LM, Wood E, Montaner JS, Yip B, O'connell JM, Hogg RS.

J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1470-6.

PMID:
15602125
5.

Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras.

Prins M, Meyer L, Hessol NA.

AIDS. 2005 Mar 4;19(4):357-70. Review.

PMID:
15750389
6.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

PMID:
18199042
7.

Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil.

Grinsztejn B, Veloso VG, Pilotto JH, Campos DP, Keruly JC, Moore RD.

J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):515-20.

PMID:
17558332
8.

Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy.

Drain PK, Kupka R, Mugusi F, Fawzi WW.

Am J Clin Nutr. 2007 Feb;85(2):333-45. Review.

9.

Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study.

Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, Swai A, Lipyoga R, Mhalu F, Biberfeld G; Mitra Plus Study Team.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):406-16. doi: 10.1097/QAI.0b013e3181b323ff.

PMID:
19730269
10.

Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care.

Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, Bebawy S, Kheshti A, Sterling TR, Raffanti SP.

J Infect Dis. 2009 Apr 1;199(7):991-8. doi: 10.1086/597124.

PMID:
19220139
11.

Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men.

Ostrow DE, Fox KJ, Chmiel JS, Silvestre A, Visscher BR, Vanable PA, Jacobson LP, Strathdee SA.

AIDS. 2002 Mar 29;16(5):775-80.

PMID:
11964534
12.

Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care.

Weintrob AC, Grandits GA, Agan BK, Ganesan A, Landrum ML, Crum-Cianflone NF, Johnson EN, Ordóñez CE, Wortmann GW, Marconi VC; IDCRP HIV Working Group.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):574-80. doi: 10.1097/QAI.0b013e3181b98537.

PMID:
19755913
13.

Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons.

Boulassel MR, Morales R, Murphy T, Lalonde RG, Klein MB.

J Med Virol. 2006 Sep;78(9):1158-63.

PMID:
16847953
14.

Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.

Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G; Italian MASTER Cohort.

Antivir Ther. 2007;12(6):941-7.

PMID:
17926648
15.

Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study.

Moore AL, Sabin CA, Johnson MA, Phillips AN.

J Acquir Immune Defic Syndr. 2002 Feb 1;29(2):197-202.

PMID:
11832692
16.

One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients.

Park WB, Choe PG, Kim SH, Jo JH, Bang JH, Kim HB, Kim NJ, Oh M, Choe KW.

J Intern Med. 2007 Mar;261(3):268-75.

17.

Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.

Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, Bostrom A, O'Hare AM.

Clin Infect Dis. 2007 Dec 15;45(12):1633-9. doi: 10.1086/523729.

PMID:
18190326
18.

Impact on weight and height with the use of HAART in HIV-infected children.

Guillén S, Ramos JT, Resino R, Bellón JM, Muñoz MA.

Pediatr Infect Dis J. 2007 Apr;26(4):334-8.

PMID:
17414398
19.

Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, Liñares J, Gudiol F; Spanish Pneumococcal Infection Study Network (G03/103).

Arch Intern Med. 2005 Jul 11;165(13):1533-40.

PMID:
16009870
20.

Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting.

Torti C, Casari S, Palvarini L, Quiros-Roldan E, Moretti F, Leone L, Patroni A, Castelli F, Ripamonti D, Tramarin A, Carosi G.

Health Policy. 2003 Sep;65(3):261-7.

PMID:
12941493

Supplemental Content

Support Center